The last several years have seen significant growth in the number and utilization of specialty drugs. Cancer immunotherapy, in particular, has experienced growth in the number of available treatments, oftentimes offering a lifeline for otherwise terminal conditions. CAR T-cell therapy, immunotherapy approved for several types of cancer, is one of the new biologics that has entered the market. Although CAR T-cell therapy is currently approved by the Food and Drug Administration (FDA)to treat several rare cancers , there is reason to believe that the indications for this therapy will expand over the next several years, carrying significant implications for both patients and employers. This Action Brief will review what CAR T-cell therapy is, what the future of this treatment is likely to look like, and what this means in terms of value and cost. https://www.gpbch.org/docs/mbgh_cart_cobrand.pdf